A Single Patient Study of Sapropterin for Multisystem Smooth Muscle Dysfunction Syndrome

Starting soon · Not applicable

Conditions studied: Multisystemic Smooth Muscle Dysfunction Syndrome

In brief

There is currently no approved treatment for multisystem smooth muscle dysfunction syndrome (MSMDS). This single-patient study is the first to be conducted in a child with MSMDS in Canada and was designed to provide the child with access to sapropterin treatment. The molecule we will be using, sapropterin (Kuvan), is already approved and available for other indications. This disease is caused by a genetic variant in the ACTA2 gene. This variant prevents the small units of actin fibers, which are the molecular motors of the smooth muscle cell, from assembling correctly. The goal is to gather data so that the drug can be approved for this indication and thus treat the patient.

Key facts

Study ID

NCT07574034

Run by

Gregor Andelfinger

People needed

1

Starts

2026-06-01

Expected to finish

2030-06-01

Last updated by the study team

2026-05-07

Who can join

Age: 0 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with the following molecularly confirmed genotype: ACTA2 c.536G>A, p.Arg179His
• Aged 1 month to 18 years

You may not qualify if…

• Previous exposure to Kuvan®, Biopten®, or any preparation of tetrahydrobiopterin for greater
• Known hypersensitivity to Kuvan® or its excipients
• Known hypersensitivity to other approved or non-approved formulations of tetrahydrobiopterin
• Current use of medications that are known to affect nitric oxide synthesis, metabolism or action
• Current use of experimental/other investigational or unregistered drugs that may affect the study outcomes
• Inability to comply with study procedures
• Concurrent disease or condition that would interfere with study participation or increase the risk for adverse events, including stroke, renal or hepatic failure
• Other significant disease that in the Investigator's opinion would exclude the subject from the trial
• Any condition that, in the view of the Principal Investigator renders the subject at high risk for failure to comply with treatment or to complete the study

Where it is running

• CHU Sainte-Justine — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.